Treatment with tofacitinib in refractory psoriatic arthritis. National multicenter study of the first 87 patients of clinical practice

Psoriatic Arthritis

Disease features associated with a low disease impact in patients with psoriatic arthritis: results of a cross-sectional multicenter study

Arthritis Res Ther.

Queiro R, Cañete JD, Montoro M, Gómez S, Cábez A, MAAPS study group.

doi: 10.1186/s13075-020-02168-1.

Psoriatic Arthritis

Long-term etanercept survival in patients with psoriatic arthritis: a multicenter retrospective analysis in daily clinical practice in Spain

Rheumatol Int.

Deza G, Notario J, Ferran M, Beltrán E, Almirall M, Alcalá R, Ruiz-Carrascosa JC, Sánchez R, Pérez S, García-Vivar ML, Galíndez E, Mora M, Rodríguez J, Gallardo F

doi: 10.1007/s00296-018-4144-8.

Psoriatic Arthritis

Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study

Rheumatol Ther.

Nash P, Coates LC, Kivitz AJ, Mease PJ, Gladman DD, Covarrubias-Cobos JA, FitzGerald O, Fleishaker D, Wang C, Wu J, Hsu MA, Menon S, Fallon L, Romero AB, Kanik KS

doi: 10.1007/s40744-020-00209-4.

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Comparative study of infliximab versus adalimumab in refractory uveitis due to Behçet's disease, National multicenter study of 177 cases

Arthritis Rheumatol.

Atienza-Mateo B, Martín-Varillas JL, Calvo-Río V, Demetrio-Pablo R, Beltrán E, Sánchez-Bursón J, Mesquida M, Adan A, Hernández MV, Hernández-Garfella M, Valls-Pascual E, Martínez-Costa L, Sellas-Fernández A, Cordero-Coma M, Díaz-Llopis M, Gallego R, García-Serrano JL, Ortego-Centeno N, Herreras JM, Fonollosa A, Garcia-Aparicio ÁM, Maíz-Alonso O, Blanco A, Torre-Salaberri I, Fernandez-Espartero C, Jovaní V, Peiteado D, Pato E, Cruz J, Férnandez-Cid C, Aurrecoechea E, García-Arias M, Castañeda S, Caracuel-Ruiz MA, Montilla-Morales CA, Atanes-Sandoval A, Francisco F, Insua S, González-Suárez S, Sanchez-Andrade A, Gamero F, Linares Ferrando LF, Romero-Bueno F, García-González AJ, Raquel AG, Minguez Muro E, Carrasco-Cubero C, Olive A, Prior Á, Vázquez J, Ruiz-Moreno O, Jiménez-Zorzo F, Manero J, Muñoz Fernandez S, Fernández-Carballido C, Rubio-Romero E, Pages FA, Toyos-Sáenz de Miera FJ, Gandia Martinez M, Díaz-Valle D, López Longo FJ, Nolla JM, Raya Álvarez E, Revenga Martínez M, González-López JJ, Rodríguez-Cundin P, Hernández JL, González-Gay MA, Blanco R

doi: 10.1002/art.41026.

Further Publications Rheumatology

Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis

Arthritis Res Ther

Rahman P, Mease PJ, Helliwell PS, Deodhar A, Gossec L, Kavanaugh A, Kollmeier AP, Hsia EC, Zhou B, Lin X, Shawi M, Karyekar CS, Han C

doi: 10.1186/s13075-021-02554-3

Psoriatic Arthritis

Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis

Arthritis Res Ther.

Combe B, Rahman P, Kameda H, Cañete JD, Gallo G, Agada N, Xu W, Genovese MC

doi: 10.1186/s13075-020-2099-0.

Psoriatic Arthritis

Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study

Semin Arthritis Rheum.

Coates LC, Nash P, Kvien TK, Gossec L, Mease PJ, Rasouliyan L, Pricop L, Jugl SM, Gandhi KK, Gaillez C, Smolen JS

doi: 10.1016/j.semarthrit.2020.03.015.

Psoriatic Arthritis

2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis

Arthritis Rheumatol.

Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J

doi: 10.1002/art.40726.

Psoriatic Arthritis

Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies

J Eur Acad Dermatol Venereol.

Merola JF, Papp KA, Nash P, Gratacós J, Boehncke WH, Thaçi D, Graham D, Hsu MA, Wang C, Wu J, Young P

doi: 10.1111/jdv.16433.

Related content

Disease features associated with a low disease impact in patients with psoriatic arthritis: results of a cross-sectional multicenter study

Long-term etanercept survival in patients with psoriatic arthritis: a multicenter retrospective analysis in daily clinical practice in Spain

Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study

Comparative study of infliximab versus adalimumab in refractory uveitis due to Behçet's disease, National multicenter study of 177 cases

Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis

Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis

Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study

2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis

Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies